6mhp
Vaccineexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2003 (NCT00089219)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 6mhp
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04364230 | Phase 1/Phase 2 (Phase 2) | May 8, 2020 | Celldex Therapeutics, University of Virginia |
| NCT03617328 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2018 | University of Virginia |
| NCT02382549 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2016 | National Cancer Institute (NCI), University of Virginia |
| NCT02515227 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2015 | National Cancer Institute (NCI), University of Virginia |
| NCT02425306 | Phase 1/Phase 2 (Phase 2) | May 1, 2015 | Cancer Research Institute, Ludwig Institute for Cancer Research, University of Virginia |
| NCT02385669 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2015 | University of Virginia |
| NCT00089219 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2003 | National Cancer Institute (NCI), University of Virginia |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Virginia | Academic/Hospital | 7 | 7 | 1 | 2003 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 1 | 2003 |
| Cancer Research Institute | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Celldex Therapeutics | For profit | 1 | 0 | 1 | 2020 |
| Ludwig Institute for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1